Abstract: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.
Abstract: The invention concerns a method for preparing native collagen, comprising pretreatment of the collagen in a mixer with double transverse cutters equipped with a system controlling agitating and shearing velocity and a thermostat, and a subsequent step of sterilizing the collagen in liquid medium. The invention also concerns a sterile collagen, in particular a collagen mostly of type I, in native state and in particular pharmaceutical and/or parapharmaceutical and/or medico-surgical and/or ophthalmologic and/or cosmetic compositions and applications thereof.
Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 24, 2000
Assignee:
Octapharma AG
Inventors:
Lothar Biesert, Horst Schwinn, Wolfgang Marguerre
Abstract: The method for the aptitude testing of protein fractions containing factor VIII the further processing of which comprises a pasteurizing step is performed in such a way that the starting material is examined for fragments within a range of from 20 to 50 kD. Fragments of factor VIII within this range evidently cause inhibitor formations in patients pretreated with factor VIII. Batches contaminated with such fragments can also be utilized, i.e., for the preparation of a high purity virus-free factor VIII by size exclusion chromatography on hydrophilic materials.
Type:
Grant
Filed:
January 7, 1999
Date of Patent:
May 2, 2000
Assignee:
Octapharma AG
Inventors:
Andrea Buchacher, Monika Stadler, DJuro Josic
Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.
Type:
Grant
Filed:
February 19, 1998
Date of Patent:
December 28, 1999
Assignee:
Octapharma AG
Inventors:
Wolfgang Marguerre, Horst Schwinn, Lothar Biesert
Abstract: A process for the preparation of factor IX from a biological source by chromatography involves prior treatment with ammonium sulfate as a protein precipitant at a concentration of from 1.5-2.3 mol/l.
Type:
Grant
Filed:
November 26, 1997
Date of Patent:
July 6, 1999
Assignee:
Octapharma AG
Inventors:
Djuro Josic, Lutz Hoffer, Frank Morfeld
Abstract: Described is an economical process for the recovery of factor VIII from blood plasma or cryoprecipitate. In the process, anion exchanger chromatography is conducted using a separating material based on carriers containing hydroxyl groups, the surfaces of which carriers have been coated with covalently boded polymers. The polymers contain repeating units represented by formula (I).
Abstract: This invention describes a process for preparing virus-inactivated immunoglobulin solutions suitable for intra-venous application, characterized in that the immunoglobulin is treated with non-ionic surfactants which subsequently are removed by solid-phase extraction on hydrophobic materials.
Abstract: A stable, injectable solution containing factor VIII suitable for the treatment of humans, natural or synthetic disaccharides, preferably saccharose, in concentrations of from 0.1 to 0.65 mol/1, and one or more amino acids in concentrations of from 0.1 to 1.0 mol/1. A process for preparing same and the use of natural or synthetic disaccharides, preferably saccharose, and one or more amino acids for stabilizing factor VIII.